Search Results for

The Biden Administration was elected to office with an urgent mandate to change our current trajectory towards catastrophic climate change. Climate-focused financial regulation, or the regulation of markets to accurately account for climate risk and the social and material costs of climate-damaging activities, must be a part of this coordinated federal response in order to meaningfully address climate concerns at the governmental level. An agency that is particularly key to this goal is the Commodity Futures Trading Commission (CFTC). The CFTC is one of the smallest federal financial regulatory bodies and yet it is responsible for regulating one of the country’s largest markets, derivatives. While it was originally founded to regulate futures trading in commodities, the passage of the Dodd-Frank Wall Street Reform and Consumer Protection Act in 2010 expanded the CFTC’s mandate to include swaps markets and broadened the agency’s role in regulating other derivatives, in part due to their extreme volatility and outsized role in the 2008 financial crisis. 

Dr. Robert Califf appears to be the clearest front-runner for the (somehow) still open position of commissioner of the Food and Drug Administration. After floating his name in the press a few weeks ago, President Biden recently met with Califf in private. Such meetings tend to be the final step before a nominee is announced.

There’s just one problem: Califf is a longtime political consultant to Big Pharma and, more recently, to Big Tech. In fact, he’s so tied to those industries that he once earned the ire of a certain crucial senator from West Virginia.